Hims & Hers Health, Inc. (HIMS) Securities Fraud Class Action Lawsuit Filed; November 2, 2026, Lead Plaintiff Deadline

Did you buy HIMS securities between August 4, 2025 and July 29, 2026? Affected HIMS Investor Summary Who: Hims & Hers Health, Inc. (NYSE: HIMS ) What: Securities fraud class action lawsuit filed Class Period: August 4, 2025 through July 29, 2026 Deadline to Seek Lead Plaintiff Status: November 2, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's deceptive and unlawful privacy practices Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com ) for recovery options Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) , a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS) (NYSE: HIMS ) on behalf of those who purchased or acquired HIMS securities between August 4, 2025 and July 29, 2026, inclusive. The lawsuit is filed in the United States District Court for the Northern District of California and is captioned Velanki v. Hims & Hers Health, Inc., No. 26-cv-09313 (N.D. Cal.). Investors have until November 2, 2026, to file for lead plaintiff status. If you purchased or acquired HIMS securities and have lost money on your investment, please provide your information here: https://www.ktmc.com/hims-hims-hers-inc-class-action-lawsuit?utm_campaign=hc?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=hims&mktm=PR You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected] . There is no cost or obligation to speak with an attorney. The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) HIMS shared consumers' health information with third-party advertising platforms; (2) HIMS charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them;" (3) the foregoing conduct subjected HIMS to regulatory scrutiny; (4) as a result, HIMS was reasonably likely to incur fees and penalties; and (5) as a result of the foregoing, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Why did HIMS's Stock Drop? On July 29, 2026, the Federal Trade Commission ("FTC") filed a lawsuit against HIMS accusing the company of sharing customers' medical information with third-party advertisers. Specifically, the FTC's criminal complaint accuses HIMS of "deceptive and unlawful privacy practices," including sharing sensitive details about a patient's health with Snap and Facebook parent, Meta Platforms. On this news, HIMS's stock price declined $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026. HIMS investors may, no later than November 2, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually t...